YMRC
RLAY icon

Yorktown Management & Research Company’s Relay Therapeutics RLAY Stock Holding History

Yorktown Management & Research Company’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Buy
+23,200
New +$337K 0.27% 139

Other funds holding RLAY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

Yorktown Management & Research Company's RLAY Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 23,200 shares worth $434K. The stake represents 0.27% of the portfolio and ranks #139 among its holdings.

29 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Yorktown Management & Research Company held 23,200 shares of Relay Therapeutics worth $434K as of Q2 2026.
  • Relay Therapeutics was a new Yorktown Management & Research Company position in Q2 2026.
  • Relay Therapeutics made up 0.27% of Yorktown Management & Research Company's portfolio in Q2 2026, its #139 holding.
  • 29 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.